Results 61 to 70 of about 92,765 (376)

Dl-3-n-butylphthalide inhibits phenytoin-induced neuronal apoptosis in rat hippocampus and cerebellum [PDF]

Journal of Integrative Neuroscience, 2019
Rats were divided into six groups: sham/control, Dl-3-n-butylphthalide, P1 (low phenytoin, 100 mg/kg), P2 (high phenytoin, 200 mg/kg), NP1 (Dl-3-n-butylphthalide 80 mg/kg, phenytoin 100 mg/kg), NP2 (Dl-3-n-butylphthalide 80 mg/kg, phenytoin 200 mg/kg ...
Junmin Chen, Na Liu, Xiaopeng Wang, Yanying Zhao, Junna He, Lan Yang, Qian Sun, Jing Zhao, Linjing Wang, Lei Chen
doaj   +1 more source

Identification of New KCNT1‐Epilepsy Drugs by In Silico, Cell, and Drosophila Modeling

Annals of Neurology, EarlyView.
Objective Hyperactive KCNT1 potassium channels, caused by gain‐of‐function mutations, are associated with a range of epilepsy disorders. Patients typically experience drug‐resistant seizures and, in cases with infantile onset, developmental regression can follow.
Michael G. Ricos, Bethan A. Cole, Rashid Hussain, Grigori Y. Rychkov, Zeeshan Shaukat, Nadia Pilati, Stephen P. Muench, Katie J. Simmons, Leanne M. Dibbens, Jonathan D. Lippiat   +9 more
wiley   +1 more source

CO carbonylation and first evaluation as a P-gp tracer in rats [PDF]

, 2012
BACKGROUND: At present, several positron emission tomography (PET) tracers are in use for imaging P-glycoprotein (P-gp) function in man. At baseline, substrate tracers such as R-[(11)C]verapamil display low brain concentrations with a distribution volume
Eriksson, P.A.J., Labots, M., Lammertsma, A.A., Lange, E.C.M. de, Mooijer, M.P.J., Rongen, M., Syvanen, S., Verbeek, J., Voskuyl, R.A., Windhorst, A.D.   +9 more
core   +2 more sources

Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels

British Journal of Clinical Pharmacology, EarlyView.
This review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene–drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or ...
Guilherme Suarez‐Kurtz
wiley   +1 more source

Phenytoin Penetration into Brain After Administration of Phenytoin or Fosphenytoin [PDF]

Epilepsia, 1999
Summary: Purpose: This study was designed to measure the brain penetration of phenytoin (PHT) after intravenous (i.v.) administration of either standard PHT or fosphenytoin (FPHT), a PHT prodrug. The study was formulated to answer the question whether the time required for FPHT to be converted to PHT in the bloodstream would delay the accumulation of
K. El Yafi, N. Y. Walton, Jae Moon Kim, Basim M. Uthman, David M. Treiman   +4 more
openaire   +3 more sources

Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein. [PDF]

, 2016
BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). These studies were all of short duration, and some drugs,
Chervoneva, Inna, Miller, Rachael, Mintzer, Scott, Nei, Maromi, Shah, Krunal, Skidmore, Christopher T., Sperling, Michael R.   +6 more
core   +2 more sources

Voclosporin‐induced gingival enlargement: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca, Jessica M. Greco, Dimitris N. Tatakis   +2 more
wiley   +1 more source

Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter‐Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™)

Clinical Pharmacology &Therapeutics, EarlyView.
Accurate prediction of oral drug absorption in humans is essential for early drug development; however, physiologically relevant human models are lacking. This study aims to comprehensively assess the EpiIntestinal™, a human primary intestinal 3D model, for its ability to predict oral absorption (Fa), intestinal availability (Fg), CYP3A4 induction, and
Paresh P. Chothe, Andrea Whitcher‐Johnstone, Aniruddha Karve, Diane Ramsden, Niresh Hariparsad   +4 more
wiley   +1 more source

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

Clinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni, Chin Hang Yiu, Mohammad A. Ali, Christine Y. Lu   +3 more
wiley   +1 more source

Unmet needs of women with epilepsy living in rural low‐ and middle‐income countries: The experience of the Bolivian Chaco

Epilepsia Open, EarlyView.
Abstract Objective Epilepsy affects approximately 70 million people worldwide, with 80% living in low‐ and middle‐income countries (LMICs), where many people with epilepsy (PWE) go undiagnosed or untreated. Over the last few decades, many efforts have been made worldwide to reduce the treatment gap (TG) in LMICs.
Alessandra Nicoletti, Gianluca Latino, Calogero Edoardo Cicero, Anna Barbiero, Chiara Aguzzoli, Bianca Ribelli, Valentina Petrini, Maria Micieli, Sandra Padilla, Estela Vilte, Francesco Cosmi, Elizabeth Blanca Crespo Gomez, Alessandro Bartoloni, Loretta Giuliano   +13 more
wiley   +1 more source